136 results on '"Meric-Bernstam, Funda"'
Search Results
2. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer
3. Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
4. Artificial intelligence in clinical and translational science: Successes, challenges and opportunities
5. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified
6. Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF ‐mutated advanced cancers
7. Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer
8. Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors
9. Clinical and molecular characterization of early‐onset colorectal cancer
10. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF ‐mutated melanoma and other advanced malignancies
11. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
12. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels
13. Physician interpretation of genomic test results and treatment selection
14. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
15. Biliary cancer: Utility of next-generation sequencing for clinical management
16. Toward Personalized Therapy for Cancer
17. Hepatocellular carcinoma: Where there is unmet need
18. Attitudes toward molecular testing for personalized cancer therapy
19. Chemotherapy: Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site- and Sequence-Specific Drug Release (Adv. Funct. Mater. 30/2014)
20. The role of surgeons in building a personalized medicine program
21. Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site- and Sequence-Specific Drug Release
22. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer
23. Genotype inBRCA-associated Breast Cancers
24. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer
25. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer
26. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer
27. Molecular-targeted nanotherapies in cancer: Enabling treatment specificity
28. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer
29. Earlier age of onset ofBRCAmutation-related cancers in subsequent generations
30. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ
31. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
32. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
33. Nanomedicine in cancer therapy: Innovative trends and prospects
34. HER2 studies look promising
35. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy
36. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
37. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment
38. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer
39. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients
40. False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden
41. Perception of screening and risk reduction surgeries in patients tested for aBRCAdeleterious mutation
42. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer
43. The impact of pregnancy on breast cancer outcomes in women ≤35 years
44. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy
45. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?
46. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy
47. Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer
48. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases
49. Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response
50. Feasibility and Accuracy of Sentinel Lymph Node Biopsy After Preoperative Chemotherapy in Breast Cancer Patients With Documented Axillary Metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.